DBV Technologies S.A. (DBVT) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed DBV Technologies S.A. (DBVT) over the past year, gaining 91.1% versus a loss of 31.4%. Over five years, DBVT leads with a -7.8% price change compared with -55.0% for SLN. DBV Technologies S.A. is the larger company by market cap ($588.9 million vs $566.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | SLN |
|---|---|---|
| Share price | $9.37 | $9.12 |
| Market cap | $588.89M | $566.71M |
| 1-day change | -4.09% | -7.15% |
| YTD return | -49.03% | +61.51% |
| 1-year return | -31.39% | +91.05% |
| 5-year return | -7.83% | -55.00% |
| EPS (TTM) | $-3.50 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.19 | $17.58 |
| 52-week low | $9.36 | $4.19 |
| Distance from 52-week high | -64.22% | -48.12% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +312.27% | +261.93% |
| Average volume | 331.54K | 1.12M |
| Shares outstanding | 62.85M | 62.15M |
| Employees | 170 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed DBVT by 122.4 percentage points over the past year.
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 170 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
DBVT vs SLN FAQ
Which is bigger, DBV Technologies S.A. or Silence Therapeutics Plc American Depository Share?
DBV Technologies S.A. (DBVT) is larger, with a market capitalization of $588.89M compared with $566.71M for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, DBVT or SLN?
SLN returned +91.05% over the past 12 months, compared with -31.39% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are DBV Technologies S.A. and Silence Therapeutics Plc American Depository Share in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for DBV Technologies S.A. and Biotechnology: Pharmaceutical Preparations for Silence Therapeutics Plc American Depository Share.